Pacific Biosciences of California Posts Big Third Quarter Loss
So far in 2017, Pacific Biosciences of California (NASDAQ: PACB), also known as PacBio, has yet to report impressive quarterly results. In August, the genetic-sequencing company reported big losses for the second quarter as it had done in the first quarter.
Despite the dismal financial results, PacBio stock has had an up-and-down year. By early September, the company's share price was up more than 45% year to date. However, since then PacBio stock has fallen quite a bit.
PacBio announced its third-quarter results after the market closed on Thursday. The losses continued, but there were some bright spots. Here are the highlights from the company's quarterly update.
Source: Fool.com
Pacific Biosciences of California Inc. Aktie
1,63 €
8,33 %
Leichte Kaufstimmung für Pacific Biosciences of California Inc.: Mehr Buy- als Sell-Einschätzungen.
Mit einem Community-Kursziel von 9 € für Pacific Biosciences of California Inc. wird ein starkes Wachstumspotenzial gegenüber dem aktuellen Kurs von 1.63 € gesehen.
